NCT06885645View on ClinicalTrials.gov

First-In-Human Study in Participants With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Advanced Solid Tumors
Interventions
DRUG

KH815 for injection

KH815 for injection is a dual-payload Antibody Drug Conjugate (ADC) targeting TROP2 antigens.

All Listed Sponsors
lead

Chengdu Kanghong Biotech Co., Ltd.

INDUSTRY

NCT06885645 - First-In-Human Study in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter